In vitro assays demonstrated its robust cytotoxicity against CD19+CD133+ and CD19−CD133+ B cells, which could help reduce the subsequent lineage switch in MLL-r B-ALL [278]. This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.